References of "ABRAHAMSEN, B"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailIdentification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting.
Kanis, J.A.; Cooper, C.; Rizzoli, R. et al

in Osteoporosis International (2017), 28(7), 2023-2034

Summary: Osteoporosis represents a significant and increasing healthcare burden in Europe, but most patients at increased risk of fracture do not receive medication, resulting in a large treatment gap ... [more ▼]

Summary: Osteoporosis represents a significant and increasing healthcare burden in Europe, but most patients at increased risk of fracture do not receive medication, resulting in a large treatment gap. Identification of patients who are at particularly high risk will help clinicians target appropriate treatment more precisely and cost-effectively, and should be the focus of future research. Introduction: The purpose of the study was to review data on the identification and treatment of patients with osteoporosis at increased risk of fracture. Methods: Aworking group convened by the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis met to review current data on the epidemiology and burden of osteoporosis and the patterns of medical management throughout Europe. [less ▲]

Detailed reference viewed: 27 (3 ULiège)
Full Text
Peer Reviewed
See detailInternational Osteoporosis Foundation and European Calcified Tissue Society working group. Recommendations for the screening of the adherence to oral bisphosphonates.
DIEZ-PEREZ, A; NAYLOR, K.E.; ABRAHAMSEN, B et al

in Osteoporosis International (2017), 28(3), 767-774

Summary: Adherence to oral bisphosphonates is low. A screening strategy is proposed based on the response of biochemical markers of bone turnover after 3 months of therapy. If no change is observed, the ... [more ▼]

Summary: Adherence to oral bisphosphonates is low. A screening strategy is proposed based on the response of biochemical markers of bone turnover after 3 months of therapy. If no change is observed, the clinician should reassess the adherence to the treatment and also other potential issues with the drug. Introduction: Low adherence to oral bisphosphonates is a common problem that jeopardizes the efficacy of treatment of osteoporosis. No clear screening strategy for the assessment of compliance is widely accepted in these patients. Methods: The International Osteoporosis Foundation and the European Calcified Tissue Society have convened a working group to propose a screening strategy to detect a lack of adherence to these drugs. The question to answer was whether the bone turnover markers (BTMs) PINP and CTX can be used to identify low adherence in patients with postmenopausal osteoporosis initiating oral bisphosphonates for osteoporosis. The findings of the TRIO study specifically address this question and were used as the basis for testing the hypothesis. Results: Based on the findings of the TRIO study, specifically addressing this question, the working group recommends measuring PINP and CTX at baseline and 3 months after starting therapy to check for a decrease above the least significant change (decrease of more than 38% for PINP and 56% for CTX). Detection rate for the measurement of PINP is 84%, for CTX 87% and, if variation in at least one is considered when measuring both, the level of detection is 94.5%. Conclusions: If a significant decrease is observed, the treatment can continue, but if no decrease occurs, the clinician should reassess to identify problems with the treatment, mainly low adherence. [less ▲]

Detailed reference viewed: 22 (4 ULiège)
Full Text
Peer Reviewed
See detailErratum to: Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting (Osteoporosis International, (2017), 28, 7, (2023-2034), 10.1007/s00198-017-4009-0)
Kanis, J. A.; Cooper, C.; Rizzoli, R. et al

in Osteoporosis International (2017), 28(11), 3285-3286

The article “Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting”, written by J.A. Kanis, C. Cooper, R. Rizzoli, B ... [more ▼]

The article “Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting”, written by J.A. Kanis, C. Cooper, R. Rizzoli, B. Abrahamsen, N. M. Al-Daghri, M. L. Brandi, J. Cannata-Andia, B. Cortet, H. P. Dimai, S. Ferrari, P. Hadji,N. C. Harvey, M. Kraenzlin, A. Kurth, E. McCloskey, S. Minisola17, T. Thomas, and J.-Y. Reginster for the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), was originally published Online First without open access. After publication in volume 28, issue 7, pages 2023–2034 the author decided to opt for Open Choice and to make the article an open access publication. Therefore, the copyright of the article has been changed to © The Author(s) 2017 and the article is forthwith distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/ licenses/by/4.0/), which permits use, duplication, adaptation, distribution and reproduction in any medium or format, as long as appropriate credit is given to the original author(s) and the source, a link to the Creative Commons license is provided, and any changes made are indicated. © International Osteoporosis Foundation and National Osteoporosis Foundation 2017. [less ▲]

Detailed reference viewed: 17 (0 ULiège)
Full Text
Peer Reviewed
See detailTraitement par denosumab chez des hommes à masse osseuse basse: résultats à 24 mois de l'étude ADAMO
Chapurlat, R.; Langdahl, B.; Teglbjaerg, C. et al

in Revue du Rhumatisme (2015, November), 82(S1), 123-124

Detailed reference viewed: 28 (7 ULiège)
Full Text
Peer Reviewed
See detailDenosumab for the treatment of men with low bone mineral density: 24-month results from the Adamo Trial
Langdahl, B; Teglbjaerg, C; Ho, PR et al

in Endocrine Reviews (2014), 35(3), 22-1

Detailed reference viewed: 26 (2 ULiège)
Full Text
Peer Reviewed
See detailA randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density
Orwoll, E.; Teglbjærg, C. S.; Langdahl, B. L. et al

in Journal of Clinical Endocrinology and Metabolism (2012), 97(9), 3161-3169

Context: Men with low bone mineral density (BMD) were treated with denosumab. Objective: Our objective was to investigate the effects of denosumab compared with placebo in men with low BMD after 1 yr of ... [more ▼]

Context: Men with low bone mineral density (BMD) were treated with denosumab. Objective: Our objective was to investigate the effects of denosumab compared with placebo in men with low BMD after 1 yr of treatment. Design, Subjects, and Intervention: This was a placebo-controlled, phase 3 study to investigate the efficacy and safety of denosumab 60 mg every 6 months vs. placebo in men with low BMD. Main Outcome Measure: The primary endpoint was the percent change from baseline in lumbar spine (LS) BMD at month 12. Results: Of the 242 randomized subjects (mean age 65 yr), 228 (94.2%) completed 1 yr of denosumab therapy. After 12 months, denosumab resulted in BMD increases of 5.7% at the LS, 2.4% at the total hip, 2.1% at the femoral neck, 3.1% at the trochanter, and 0.6% at the one third radius (adjusted P≥0.0144 for BMD percent differences at all sites compared with placebo). Sensitivity analyses done by controlling for baseline covariates (such as baseline testosterone levels, BMD T-scores, and 10-yr osteoporotic fracture risk) demonstrated that the results of the primary endpoint were robust. Subgroup analyses indicate that treatment with denosumab was effective across a spectrum of clinical situations. Treatment with denosumab significantly reduced serum CTX levels at d 15 (adjusted P < 0.0001). The incidence of adverse events was similar between groups. Conclusions: One year of denosumab therapy in men with low BMD was well tolerated and resulted in a reduction in bone resorption and significant increases in BMD at all skeletal sites assessed. Copyright © 2012 by The Endocrine Society. [less ▲]

Detailed reference viewed: 25 (2 ULiège)
Full Text
Peer Reviewed
See detailAntidepressant medications and osteoporosis
Rizzoli, R; Cooper, C; Reginster, Jean-Yves ULiege et al

in BONE (2012), 51

Detailed reference viewed: 31 (2 ULiège)
Full Text
Peer Reviewed
See detailA phase 3 study of the efficacy and safety of Denosumab in men with low bone mineral density : design of the ADAMO
Orwoll, E.; Stubbe Teglbjaerg, Ch; Langdahl, B. et al

in Journal of Bone and Mineral Research (2011), 26(S1), 511

Detailed reference viewed: 59 (2 ULiège)